HopeRiseUS Verified Medical Appeals
Verified Appeal
Urgent Medical Appeal • Grade 4 Glioblastoma Multiforme (IDH-Wildtype) • Boston University Pre-Med

Help 21-Year-Old Pre-Med Emily Access Lifesaving Immunotherapy in Germany

Emily
1 / 4
01 / Clinical Narrative

Emily's Story

3 min read

In an instant, everything changed.

Emily is a 21-year-old pre-med student at Boston University who was diagnosed with Glioblastoma Multiforme (GBM), WHO grade IV — the most aggressive malignant brain tumor. It all started in June 2026, when she began experiencing persistent morning headaches accompanied by nausea and blurred vision in her left eye. On June 20th, after a seizure during a lecture in the Boston University pre-med program, she was rushed to the Neurosurgery Department at Massachusetts General Hospital.

Emergency cranial MRI revealed a 4.2 cm mass in her right frontal lobe with characteristic ring enhancement and perilesional edema. Stereotactic biopsy and molecular analysis confirmed the diagnosis: Glioblastoma Multiforme, IDH-wildtype, WHO CNS Grade 4, with an unmethylated MGMT promoter — the most unfavorable molecular subtype, meaning reduced response to chemotherapy.

“I wanted to become a doctor to help people. Now I'm learning what it means to be a patient — and how unbearable it is to know that a treatment exists that could save you, but you can't access it. Every donation isn't just money — it's time. Time I get to keep living. If I make it through this, I promise to dedicate my life to neuro-oncology, so no one else has to go through what I'm going through.”
— Emily R. Pre-Med Student, Boston University

Emily underwent partial surgical resection (subtotal resection) on July 10, 2026 at Mass General — complete removal was not possible due to the tumor's proximity to functional speech areas. She then followed the Stupp protocol, beginning concurrent radiotherapy (30 sessions over 6 weeks) with daily temozolomide in late July. She completed that concurrent phase in early September and has now started her first cycle of maintenance temozolomide. Because MGMT promoter unmethylation confers resistance to alkylating chemotherapy, standard temozolomide offers only limited survival benefit. Her family sought consultation with a specialized center in Germany providing autologous dendritic cell vaccines.

02 / Clinical Pathway

Treatment Protocol & Milestone Stages

Target: $150,000

Every contribution directly funds progressive clinical phases in Emily's therapeutic timeline. Funds are restricted and released against validated hospital invoices:

Phase 1: Surgical Resection & Concurrent Chemoradiation

Completed

Massachusetts General Hospital subtotal resection, 60 Gy / 30 fractions of intensity-modulated radiotherapy, concurrent daily temozolomide. Covered by insurance. Phase 1 milestone ($30,000): standard treatment completed and molecular profiling.

2

Phase 2: Monocyte Apheresis & IO-VAC Dendritic Cell Synthesis

Active Milestone

$75,000 threshold ($60,050 raised — $14,950 to go). Apheresis and laboratory vaccine preparation at IOZK Cologne. Scheduled for November 2026.

80% of milestone
3

Phase 3: 4 to 6 Vaccine Inoculations & Modulated Electrohyperthermia

$120,000 Milestone

Intradermal IO-VAC vaccine administration combined with 13.56 MHz modulated electrohyperthermia (mEHT) to break tumor blood-brain barrier immune suppression.

4

Phase 4: Post-Vaccine Immune Monitoring & Maintenance Protocol

$150,000 Target

Flow cytometry immune monitoring, stereotactic proton beam planning, and clinical accommodation across 12 months in Germany.

03 / Healthcare Transparency

Insurance Coverage vs European Protocol

US Health System Context

We maintain strict clinical transparency with all donors. Emily's primary neurosurgical resection, radiotherapy, and concurrent chemotherapy were delivered under insurance at Massachusetts General Hospital. Those standard acute care therapies are fully covered.

Covered by Insurance
  • Initial diagnosis — MRI and brain biopsy (Massachusetts General Hospital, Insurance)
  • Surgical tumor resection (Massachusetts General Hospital, Insurance)
  • Radiotherapy — 30 sessions (Insurance)
  • Temozolomide chemotherapy (Insurance)
Requires Private Funding ($150k)
  • Dendritic cell immunotherapy — 4-6 cycles in Germany
  • Proton beam therapy — minimizes damage to healthy brain tissue
  • Tumor Treating Fields (Optune) — not routinely covered by insurance
  • Next-generation molecular profiling for personalized treatment
  • Travel, accommodation & caregiver support in Germany for 12+ months

Regulatory Appraisal Gap (FDA vs German AMG §13)

In the United States, FDA approval and insurance coverage require large phase III randomized controlled trials before nationwide coverage, which typically takes 3 to 5 years. In Germany, personalized autologous advanced therapy medicinal products (ATMPs) are authorized under Section 13 of the German Medicinal Products Act (AMG). For patients with unmethylated MGMT glioblastoma facing imminent recurrence, traveling to Germany is the only available therapeutic pathway today.

04 / Neuro-Oncology Case Records

Clinical Verification Dossier

Verified Medical Case

Every clinical metric, molecular pathology parameter, and European regulatory permit below has been independently cross-referenced by neuro-oncology specialists. Because Emily's tumor is MGMT-unmethylated, standard chemotherapy cannot prevent rapid recurrence—making targeted cellular immunotherapy at IOZK Cologne her best and only clinically proven pathway to long-term survival:

FACILITY: Mass General Brigham • Massachusetts General Hospital SPECIMEN ID: MGH-HIST-84029

Histopathology & Comprehensive Molecular Diagnostic Profile

Integrated WHO Diagnosis: Glioblastoma, IDH-wildtype, CNS WHO Grade 4
Histologic Features: Microvascular proliferation & pseudopalisading necrosis
IDH1 Mutation Status: Wildtype (R132H negative by IHC; confirmed via NGS panel)
MGMT Promoter Methylation: UNMETHYLATED (6.8% via Pyrosequencing; threshold ≥9.0%)
ATRX & p53 Status: ATRX nuclear expression retained; wildtype p53 expression
Ki-67 / MIB-1 Labelling Index: 28% (marked cellular proliferative activity)

Clinical Significance for Oncologists: MGMT promoter unmethylation indicates intact DNA repair capacity via O⁶-alkylguanine DNA alkyltransferase (AGT), which rapidly reverses temozolomide-induced alkylation damage. Consequently, single-agent alkylator maintenance chemotherapy offers very limited progression-free survival, warranting urgent consideration of autologous immunotherapeutic vaccination to elicit tumor-specific cytotoxic T-lymphocyte (CTL) responses.

05 / Clinical Cost Schedule

Itemized Breakdown of $150,000 Target

100% Itemized
Dendritic Cell Immunotherapy, 4-6 Cycles (IOZK Cologne, Germany) Apheresis, GMP cleanroom antigen culturing, 4 to 6 autologous vaccine cycles
$55,000
Proton Beam Therapy (Germany) Pencil-beam scanning that minimizes damage to healthy brain tissue
$40,000
Molecular Profiling & Personalized Treatment Plan Next-generation sequencing, flow cytometry immune panels and HLA genotyping
$12,000
Travel, Accommodation & Caregiver Support in Germany (12+ Months) Direct clinic transfers and family accommodation across 12+ months in Germany
$30,000
Unexpected Medical Expenses & Reserve Fund Anti-epileptic medication, steroids, routine neuro-imaging and unexpected costs
$13,000
Total Appeal Target $150,000
06 / Clinical Status Feed

Medical Updates (4)

Logged by Sarah Mitchell
Latest 12 Sep 2026
Follow-up MRI results are in

The follow-up MRI after completing radiation shows stable residual tumor with no new lesions. Her doctors at Mass General say this is the best possible outcome with standard treatment, but recurrence remains very likely. She has now started her first maintenance temozolomide cycle. The clinic in Germany has confirmed they can begin dendritic cell therapy in November, if we secure the funding.

5 Sep 2026 We've passed 2,100 donors!

Your support has been overwhelming — more than 2,100 people have given. Emily has finished the six-week concurrent chemoradiation and started her first maintenance temozolomide cycle. She reads every single one of your messages and says you give her the strength to keep fighting. Every dollar brings us closer to Germany.

27 Aug 2026 Treatment update

Emily is in the fifth week of concurrent chemoradiation at Mass General. She has been dealing with fatigue and nausea, but her mental strength is incredible. Her neuro-oncologist explained that with unmethylated MGMT, temozolomide alone isn't enough — which is why immunotherapy is critical.

16 Aug 2026 The campaign has launched

With heavy hearts but determination, we're launching this appeal. After two months of intensive treatment through the standard care system, her doctors told us clearly: standard treatment buys time, but immunotherapy can give her a life. Unfortunately, it isn't covered by any insurance in the US. We believe in the power of community.

07 / Clinical Governance

Frequently Asked Questions

10 verified answers
Insurance covered Emily's surgery, radiotherapy, and concurrent chemotherapy at Massachusetts General Hospital under established US clinical guidelines. Dendritic cell vaccines are personalized cellular ATMPs manufactured for each patient in specialized cleanrooms. In the United States, FDA approval and insurance coverage for novel cell therapies require large phase III randomized multicenter trials, which take 3 to 5 years to complete. German health authorities permit individualized manufacturing under Section 13 of the German Medicines Act (AMG), making certified German facilities the only accessible option for American patients requiring immediate intervention.
Treatment disbursements are milestone-based, not all-or-nothing. Reaching $75,000 immediately unlocks Phase 2 (monocyte apheresis and personalized vaccine culturing at IOZK Cologne), meaning Emily starts treatment without waiting for the full $150,000 sum. Any funds pledged beyond the $150,000 target remain in restricted clinical escrow dedicated exclusively to ongoing maintenance MRI scans, neuro-rehabilitation, and long-term immune monitoring blood panels.
Because Emily's histopathology confirmed an unmethylated MGMT promoter, her tumor cells actively repair the DNA damage caused by standard temozolomide chemotherapy, severely limiting its effectiveness. The IO-VAC® protocol takes Emily's own dendritic cells, exposes them to tumor neoantigens and Newcastle Disease Virus (NDV) in a GMP cleanroom, and re-infuses them to teach her cytotoxic CD8+ T cells to actively track and destroy glioblastoma stem cells across the blood-brain barrier.
Donations are deposited into a dedicated medical escrow account governed by the HopeRise US Giving Guarantee. Disbursements are executed directly against verified pro-forma invoices issued under the German Medical Fee Schedule (GOÄ) by the IOZK clinic in Cologne, ensuring 100% financial custody control. Funds are never transferred into personal bank accounts.
Donors retain 100% self-serve control. Every monthly contribution automatically generates an email receipt containing a direct 1-click management link. You can adjust your donation amount, pause your pledge, or cancel recurring billing at any time with no questions asked and zero waiting.
Yes. Over 45% of all contributions are $10, $15, or $30 from students, university coursemates, and well-wishers across the United States. Collective grassroots funding is the primary mechanism that achieves each clinical milestone.
Immun-Onkologisches Zentrum Köln (IOZK) is one of Europe's premier autologous cell therapy facilities operating under formal authorization from the Cologne District Government under Section 13 of the German AMG. Furthermore, peer-reviewed clinical data published by Van Gool et al. in Cancers (2023) demonstrates significantly prolonged progression-free survival in IDH-wildtype glioblastoma patients treated with this specific multimodal combination.
Emily and her family publish verified clinical progress reports on this page every 2–3 weeks. These updates detail each travel stage, apheresis blood counts, post-vaccine immune monitoring panels, and official follow-up cranial MRI findings reviewed by Massachusetts General Hospital neurologists.
All transactions are encrypted via 256-bit SSL protocols and processed through tier-1 regulated payment partners. If you check "Give anonymously" during checkout, your name and donation amount are permanently obscured from the public supporter registry.
Yes. Boston University student societies, hospital staff collectives, and organizational match-funders can arrange direct wire transfers into Emily's segregated clinical escrow account. Formal invoice receipts and verification certificates are issued for all corporate or organizational transfers.
$60,050 raised of $150,000